Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.

Kardiologia polska - 1 Apr 2006

Mark Laszlo, Marki-Zay Janos, Fodor Lajos, Hajdara Ildiko, Paragh Gyorgy, Katona Andras

Abstract excerpt

BACKGROUND: Oral anticoagulants, in Hungary acenocoumarol being the one exclusively used, have a low therapeutic index and a high bleeding complication rate. The cytochrome P450 2C9 enzyme plays an important role in their metabolism. AIM: To investigate the influence of CYP2C9 polymorphism on the occurrence of bleeding complications related to acenocoumarol therapy. METHODS: Genotyping of 421 patients (183 men...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Frequency
Share to Hemorrhage
Share to Acenocoumarol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticoagulants

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2C9

Share to International Normalized Ratio

Share to Odds Ratio

Source

Identifiers

PMID: 16699986

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.PMID 16699986Read ↗

[Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Semantic proximity Read ↗

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.Semantic proximity Read ↗

Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.Semantic proximity Read ↗

VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.Semantic proximity Read ↗

Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.Semantic proximity Read ↗

Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.Semantic proximity Read ↗

Pharmacogenetics aspects of oral anticoagulants therapy.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol pharmacodynamics.Semantic proximity Read ↗

The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.Semantic proximity Read ↗

Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.Semantic proximity Read ↗

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.